TL;DR
Relapses occurring within 2 to 3 months correlated with loss of detectable CAR-NK cells, highlighting limited in vivo persistence as a principal barrier to durable response.
This first-in-human study demonstrated the feasibility of an "off-the-shelf" base-edited CAR T cell approach and informs future multiantigen strategies against AML.
How genetic modulation of NK-cell differentiation pathways may contribute to the establishment of next-generation CAR-NK cell therapies with improved durability and antitumor efficacy is discussed.
CD16HSC-NKT cells are established as a versatile and scalable cellular platform that synergizes with cusatuzumab to enhance therapeutic efficacy against RCC, and represent a promising approach to overcoming current limitations of monoclonal antibody therapy and advancing next-generation immunotherapies for solid tumors...
Pancreatic cancer (PC) remains one of the leading causes of cancer-related mortality worldwide, with most patients diagnosed at advanced stages and more than half presenting with metastatic disease at diagnosis. Although chimeric antigen receptor (CAR)-T cell therapy has shown promise for the treatment of PC, its cli...
E engineered YTS cells are positioned as a novel, scalable, and cost-effective "off-the-shelf" immunotherapy platform suitable for treating refractory leukemias and lymphomas and future studies will be required to assess safety and to explore applicability to autoimmune diseases and solid tumors.
These first clinical data support the feasibility and favorable safety profile of ATreg, a third-party, gp120-activated Treg product requiring no ex vivo expansion, and warrant further evaluation in larger prospective clinical trials.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
